UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Clinical trials for UNDIFFERENTIATED PLEOMORPHIC SARCOMA explained in plain language.
Never miss a new study
Get alerted when new UNDIFFERENTIATED PLEOMORPHIC SARCOMA trials appear
Sign up with your email to follow new studies for UNDIFFERENTIATED PLEOMORPHIC SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy aims to delay sarcoma progression
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug pembrolizumab to a targeted chemotherapy infusion (ILI with melphalan and dactinomycin) can safely delay cancer growth in people with advanced sarcoma in an arm or leg. About 30 participants aged 12 and older will receive the…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:40 UTC
-
New drug combo shows promise for Hard-to-Treat sarcomas
Disease control Recruiting nowThis study tests a combination of two drugs, pembrolizumab and cabozantinib, in people with advanced sarcomas that have not responded to standard treatments. The goal is to see if this combo can stop or shrink tumors for at least 6 months. About 119 adults with specific sarcoma t…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: PHASE2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated May 26, 2026 05:38 UTC
-
Could a pill delay relapse in bone cancer?
Disease control Recruiting nowThis study is for people with bone sarcomas who have finished their first round of treatment. It tests whether taking the drug regorafenib for up to 12 months can help keep the cancer from returning, compared to just being watched. About 168 participants will be randomly assigned…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: NA • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated May 22, 2026 14:04 UTC